Terlipressin versus placebo or noradrenalin in the treatment of hepatorenal syndrome: a systematic review and meta-analysis. [PDF]
Front PharmacolWan YM +5 more
europepmc +1 more source
Comparative Mortality Rates of Vasoconstrictor Agents in the Management of Hepatorenal Syndrome: A Systematic Review and Meta-Analysis. [PDF]
CureusOlayinka OT +6 more
europepmc +1 more source
Transjugular intrahepatic portosystemic shunts for adults with hepatorenal syndrome. [PDF]
Cochrane Database Syst RevGonzalez-Garay AG +4 more
europepmc +1 more source
Development and validation of a machine learning-based prediction model for hepatorenal syndrome in liver cirrhosis patients using MIMIC-IV and eICU databases. [PDF]
Sci RepYao F, Luo J, Zhou Q, Wang L, He Z.
europepmc +1 more source
A hospitalist's approach to managing acute kidney injury (hepatorenal syndrome) in cirrhosis. [PDF]
Clin Liver Dis (Hoboken)Giammarino A, Kalia H.
europepmc +1 more source
Retraction Note: Candesartan Protects Against Cadmium-Induced Hepatorenal Syndrome by Affecting Nrf2, NF-κB, Bax/Bcl-2/Cyt-C, and Ang II/Ang 1-7 Signals. [PDF]
Biol Trace Elem ResKamel EO +5 more
europepmc +1 more source
Related searches:
Hepatorenal syndrome (HRS) is a functional renal failure that often occurs in patients with cirrhosis and ascites. Two different types of HRS have been described. Type 1 HRS develops as a consequence of a severe reduction of effective circulating volume due to both an extreme splanchnic arterial vasodilatation and a reduction of cardiac output.
ANGELI, PAOLO +3 more
+7 more sources
Development of acute kidney injury in patients with chronic liver disease is common and portends a poor prognosis. Diagnosis remains challenging, as traditional markers, such as serum creatinine, are not reliable. Recent development of novel biomarkers may assist with this.
Saro, Khemichian +4 more
openaire +2 more sources